简体中文| English
HomeNEWS AND MEDIA

First patient dosed with MRG002 in the phase I clinical study at the Shanghai East Hospital of Tongji University

Release time：2018-11-27

Shanghai Miracogen Inc.

ADDRESS：No. 1238 Zhangjiang Rd, Building 3, Suite 4E, Pudong District, Shanghai, 201203, China

TEL：86-21-61637960

EMAIL：Info@miracogen.com.cn

ABOUT US :
Copyright 2017 Shanghai Miracogen Inc.沪ICP备17030155号